Assessing the efficacy and safety of novel drug candidates for Alzheimer's disease utilizes a rigorous evaluation system. Preclinical studies typically involve in vitro and in vivo experiments to assess a potential effectiveness in targeting disease-related pathways. Once promising candidates emerge, they undergo clinical trials that are conducted